Health & bio × Macro
FDA approves Eli Lilly oral GLP-1 'Foundayo' for obesity
The FDA approved Eli Lilly's oral GLP-1 obesity therapy orforglipron (brand name Foundayo) on April 1. Shipping via LillyDirect begins April 6 with the lowest-dose out-of-pocket price set at $149 monthly — matching Novo Nordisk's oral Wegovy head-to-head.
Primary sources · 2